JP2024123229A5 - - Google Patents

Download PDF

Info

Publication number
JP2024123229A5
JP2024123229A5 JP2024103017A JP2024103017A JP2024123229A5 JP 2024123229 A5 JP2024123229 A5 JP 2024123229A5 JP 2024103017 A JP2024103017 A JP 2024103017A JP 2024103017 A JP2024103017 A JP 2024103017A JP 2024123229 A5 JP2024123229 A5 JP 2024123229A5
Authority
JP
Japan
Prior art keywords
vamp
detection antibody
terminal
antigenic polypeptide
cleavage product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024103017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024123229A (ja
Filing date
Publication date
Priority claimed from EP16194390.7A external-priority patent/EP3312290A1/en
Application filed filed Critical
Publication of JP2024123229A publication Critical patent/JP2024123229A/ja
Publication of JP2024123229A5 publication Critical patent/JP2024123229A5/ja
Pending legal-status Critical Current

Links

JP2024103017A 2016-10-18 2024-06-26 細胞性ｖａｍｐ切断アッセイ Pending JP2024123229A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16194390.7 2016-10-18
EP16194390.7A EP3312290A1 (en) 2016-10-18 2016-10-18 Cellular vamp cleavage assay
PCT/EP2017/076569 WO2018073288A1 (en) 2016-10-18 2017-10-18 Cellular vamp cleavage assay
JP2019519721A JP7127019B2 (ja) 2016-10-18 2017-10-18 細胞性ｖａｍｐ切断アッセイ
JP2022087418A JP7656571B2 (ja) 2016-10-18 2022-05-30 細胞性ｖａｍｐ切断アッセイ

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022087418A Division JP7656571B2 (ja) 2016-10-18 2022-05-30 細胞性ｖａｍｐ切断アッセイ

Publications (2)

Publication Number Publication Date
JP2024123229A JP2024123229A (ja) 2024-09-10
JP2024123229A5 true JP2024123229A5 (https=) 2025-04-10

Family

ID=57208094

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019519721A Active JP7127019B2 (ja) 2016-10-18 2017-10-18 細胞性ｖａｍｐ切断アッセイ
JP2022087418A Active JP7656571B2 (ja) 2016-10-18 2022-05-30 細胞性ｖａｍｐ切断アッセイ
JP2024103017A Pending JP2024123229A (ja) 2016-10-18 2024-06-26 細胞性ｖａｍｐ切断アッセイ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019519721A Active JP7127019B2 (ja) 2016-10-18 2017-10-18 細胞性ｖａｍｐ切断アッセイ
JP2022087418A Active JP7656571B2 (ja) 2016-10-18 2022-05-30 細胞性ｖａｍｐ切断アッセイ

Country Status (5)

Country Link
US (2) US11193931B2 (https=)
EP (2) EP3312290A1 (https=)
JP (3) JP7127019B2 (https=)
CN (2) CN109844130B (https=)
WO (1) WO2018073288A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3202903B1 (en) 2010-12-22 2020-02-12 President and Fellows of Harvard College Continuous directed evolution
US10179911B2 (en) 2014-01-20 2019-01-15 President And Fellows Of Harvard College Negative selection and stringency modulation in continuous evolution systems
US10920208B2 (en) 2014-10-22 2021-02-16 President And Fellows Of Harvard College Evolution of proteases
WO2016168631A1 (en) 2015-04-17 2016-10-20 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
US11524983B2 (en) 2015-07-23 2022-12-13 President And Fellows Of Harvard College Evolution of Bt toxins
US10612011B2 (en) 2015-07-30 2020-04-07 President And Fellows Of Harvard College Evolution of TALENs
JP7109784B2 (ja) 2015-10-23 2022-08-01 プレジデント アンド フェローズ オブ ハーバード カレッジ 遺伝子編集のための進化したＣａｓ９蛋白質
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
WO2018081282A1 (en) * 2016-10-25 2018-05-03 Cellsnap Llc Neurotoxins and uses thereof
US11447809B2 (en) 2017-07-06 2022-09-20 President And Fellows Of Harvard College Evolution of tRNA synthetases
AU2018321405A1 (en) 2017-08-25 2020-03-05 Ipsen Biopharm Ltd. Evolution of BoNT peptidases
US11624130B2 (en) 2017-09-18 2023-04-11 President And Fellows Of Harvard College Continuous evolution for stabilized proteins
EP3752128B1 (de) * 2018-02-16 2025-01-15 preclinics discovery GmbH Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
KR102017240B1 (ko) 2018-08-23 2019-09-02 주식회사 하울바이오 Snare 복합체를 억제하는 항-vamp2 항체 및 이의 용도
US20220259269A1 (en) * 2019-07-15 2022-08-18 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US5962637A (en) * 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) * 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US6169074B1 (en) * 1996-03-18 2001-01-02 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
FR2809733B1 (fr) * 2000-06-02 2004-04-30 Inst Nat Sante Rech Med Substrat peptidique reconnu par la toxine botulique de type bont/b et son utilisation pour doser et/ou detecter ladite toxine ou des inhibiteurs correspondants
DE60130266D1 (de) * 2000-11-06 2007-10-11 Us Army Med Res Mat Command Rekombinante leichte kette des botolinum neurotoxins and fusionsproteine davon zur verwendung in forschung und klinischer therapie
GB0115581D0 (en) * 2001-06-26 2001-08-15 Glaxo Group Ltd Method of mass spectometry
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7611856B2 (en) * 2003-11-05 2009-11-03 Los Alamos National Security, Llc Mass spectrometry-based methods for detection and differentiation of botulinum neurotoxins
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
GB0425795D0 (en) 2004-11-24 2004-12-22 Givaudan Sa Composition
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
PL1877073T3 (pl) 2004-12-01 2014-03-31 The Sec Dep For Health Niecytotoksyczne koniugaty białkowe
EP1871789B1 (en) 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
WO2007106115A1 (en) 2006-03-14 2007-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US8753831B2 (en) * 2007-06-05 2014-06-17 City Of Hope Methods for detection of botulinum neurotoxin
KR101226604B1 (ko) * 2007-09-14 2013-01-28 바이오센티넬, 인코포레이티드 절단 서열 및 스페이서를 이용한 공명 에너지 전달 분석
US8940477B2 (en) * 2007-11-08 2015-01-27 Wisconsin Alumni Research Foundation Method of detecting botulinum neurotoxin and antibodies that neutralize botulinum neurotoxin action
CA2727082C (en) 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
GB0815264D0 (en) 2008-08-21 2008-09-24 Syntaxin Ltd Non-cytotoxic proteins
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US20100303791A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303783A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303788A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
KR20120062771A (ko) 2009-08-14 2012-06-14 알러간, 인코포레이티드 갈라닌 재표적화된 엔드펩티다아제를 사용하여 암을 치료하는 방법
US20110070215A1 (en) 2009-08-14 2011-03-24 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
US20110110911A1 (en) 2009-08-14 2011-05-12 Allergan, Inc Methods of Treating Cancer Using Tachykinin Retargeted Endopepidases
WO2011020052A1 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
AU2010282278A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
EP2734635A1 (en) * 2011-07-19 2014-05-28 ETH Zürich Means and methods for determining clostridial neurotoxins
US20140287433A1 (en) * 2011-07-19 2014-09-25 ETH Zürich Means and methods for determining clostridial neurotoxins
HUE037509T2 (hu) 2011-09-29 2018-09-28 Cellsnap Llc Készítmények és eljárások toxigenicitás meghatározására
SG10201606666XA (en) 2012-05-30 2016-09-29 Harvard College Engineered Botulinum Neurotoxin
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
KR20150087321A (ko) * 2012-11-21 2015-07-29 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소 생물학적 활성의 결정을 위한 수단 및 방법
GB201303108D0 (en) 2013-02-21 2013-04-10 Syntaxin Ltd Therapeutics for suppressing osteoporosis
PL3014267T3 (pl) * 2013-06-28 2019-05-31 Merz Pharma Gmbh & Co Kgaa Środki i sposoby określania aktywności biologicznej polipeptydów neurotoksyny w komórkach
GB201312295D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Suppression of itch
EP3312290A1 (en) * 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay

Similar Documents

Publication Publication Date Title
JP2024123229A5 (https=)
JP2022130378A5 (https=)
RU2491293C2 (ru) Иммунологические анализы активности ботулинического токсина серотипа а
US9000134B2 (en) Reagent and kit for early diagnosis of kidney disease
JP2021520492A5 (https=)
RU2018138782A (ru) Антитела к фактору ix padua
JP2012525563A (ja) ニューロトキシンポリペプチドの量の測定とその触媒及びタンパク質分解活性の測定のための手段及び方法
JP2001521744A5 (https=)
EP4459281A1 (en) Detection method and detection reagent
Minden et al. A chemically synthesized peptide which elicits humoral and cellular immune responses to mycobacterial antigens
EP2541252A1 (en) Method of obtaining a binder to prepro-vasopressin or fragments thereof
CN102597769B (zh) 用于测定未加工和部分加工的神经毒素a多肽的系统
EP4070112B1 (en) A neo-epitope specific assay measuring protease mediated degradation of type iv collagen
WO2006070776A1 (ja) 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法
US20200017582A1 (en) Immunoassay method using anti-human bnp fragment (4-32) antibody
RU2019113794A (ru) Анализ расщепления клеточного vamp
RU2023128330A (ru) Анализ расщепления клеточного vamp
CN121159680B (zh) 结核分枝杆菌分泌蛋白64单克隆抗体及其应用
CN112321710A (zh) 一种猫n-端脑利钠肽前体蛋白的单克隆抗体及制备和应用
CN116041527A (zh) 一种特异性结合e2-e2抗体复合物的抗体及其应用
CN121362252A (zh) 一种抗NT-proBNP的抗体及其应用
KR20250155130A (ko) 동물의 장내미생물 검출용 조성물 또는 키트
JP3610736B2 (ja) Ｈｔｌｖ−ｉｉを特異的に認識するモノクローナル抗体及び該モノクローナル抗体を産生するハイブリドーマ
CN117706079A (zh) 一种抗体定向标记生物素聚合物的方法
WO2026077075A1 (zh) 一种抗NT-proBNP的抗体及其应用